Bristol Myers drug wins first U.S. approval for Graft versus Host Disease prevention

Bristol Myers Squibb Co's (BMY.N) Orencia on Wednesday became the first drug to win U.S. approval for the prevention of acute Graft versus Host Disease (aGvHD), a potentially fatal complication that could occur after a stem cell transplant.